Compare ITRG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | TIL |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.5M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | ITRG | TIL |
|---|---|---|
| Price | $3.90 | $7.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.13 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 1.9M | 182.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $219,125,000.00 | N/A |
| Revenue This Year | $965.93 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $51.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $5.67 |
| 52 Week High | $4.69 | $42.79 |
| Indicator | ITRG | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 30.33 |
| Support Level | $3.69 | $5.67 |
| Resistance Level | $4.10 | $12.91 |
| Average True Range (ATR) | 0.23 | 0.74 |
| MACD | -0.08 | -0.23 |
| Stochastic Oscillator | 17.50 | 20.44 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.